Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching
I. Le Ray, S. Dabakuyo, G. Crehange, M. Bardou, L. Arnould, J. Fraisse, P. Fumoleau, B. Coudert, S. Causeret, P. Arveux, P. Maingon, F. BonnetainVolume:
48
Year:
2012
Language:
english
Pages:
1
DOI:
10.1016/j.ejca.2012.03.020
File:
PDF, 496 KB
english, 2012